Inhibition of angiogenesis by type I interferons in models of Kaposi's sarcoma

International Journal of Biological Markers

Volumn 14, Issue 4, 1999, Pages 257-262

  Marchisone, C ^a,b   Benelli, R ^a   Albini, A ^a   Santi, L ^a   Noonan, D M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Angiogenesis; HIV Tat; Interferon; Kaposi's sarcoma

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOATTRACTANT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; TRANSACTIVATOR PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; CELL MIGRATION; CHEMOTAXIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; HUMAN CELL; KAPOSI SARCOMA; MORPHOGENESIS; NONHUMAN; RETROVIRUS; SIDE EFFECT;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0033388527     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400411     Document Type: Conference Paper

References (37)

1. Kaposi M. Idiopathisches multiples pigment Sarcom der Haut. Arch Dermatol Syph 1872; 4: 265-73.
2. Friedman-Kien AE, Laubenstein LJ, Rubenstein P, et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982; 96: 693-700.
3. Roth WK. Brandstetter H, Stürzl M. Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS 1992; 6: 895-913.
4. Armes J. A review of Kaposi's sarcoma. Adv Cancer Res 1989; 53: 73-87.
5. Uccini S, Ruco L, Monardo F, et al. Co-expression of endothelial cell and macrophage antigens in Kaposi's sarcoma cells. J Pathol 1994; 173: 23-31.
6. Kaaya E, Parravicini C, Ordonez C, et al. Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 295-305.
7. Nickoloff BJ, Griffiths CEM. The spindle-shaped cells in cutaneous Kaposi's sarcoma. Am J Pathol 1989; 135: 793-800.
8. Popescu NC, Zimonjic DB, Leventon KS, Bryant JL, Lunardi IY, Gallo RC. Deletion and translocation involving chromosome 3 (p14) in two tumorigenic Kaposi's sarcoma cell lines. J Natl Cancer Inst 1996; 88: 450-5.
9. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpes virus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-91.
10. Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989; 243: 223-6.
11. Albini A, Fontanini G, Masiello L, et al. Angiogenic potential in vivo by Kaposi sarcoma cell-free supernatants and HIV1-tat product: inhibition of KS-like lesions by TIMP-2. AIDS 1994; 8: 1237-44.
12. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335: 606-11.
13. Corallini A, Campioni D, Rossi C, et al. Promotion of tumor metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS 1996; 10: 701-10.
14. Ensoli B, Barillari G, Salahuddin SZ, Gallo R, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345: 84-6.
15. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 89-96.
16. Bielenberg DR, McCarty MF, Bucana CD, et al. Expression of interferon-beta is associated with growth arrest of murine and human epidermal cells. J Invest Dermatol 1999; 112: 802-9.
17. Lilenbaum RC, Ratner L. Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS 1994; 8: 141-51.
18. Krown SE. Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma. J Interferon Cytokine Res 1998; 18: 209-14.
19. Nishimura J, Mitsui K, Ishikawa T, et al. Antitumor and antimetastatic activities of human recombinant interferon alpha. Clin Exp Metast 1985; 3: 295-304.
20. Hujanen ES, Turpeenniemi-Hujanen TM. Recombinant interferon-alpha modulates the invasive potential of human melanoma in-vitro. Anticancer Res 1988; 8: 1066.
21. Wadler S, Schwartz E. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473-86.
22. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562-6.
23. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci (USA) 1995; 92: 4838-42.
24. Albini A, Benelli R, Presta M, et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996; 12: 289-97.
25. Benelli R, Masiello L, Paglialunga G, et al. IFN-alpha inhibits Tat-induced angiogenesis. In HIV and cytokines, Guenounou M, eds. 1997 Les Editions INSERUM. Paris: 447-58.
26. Melchiori A, Allavena G, Bohm J, et al. Interferons inhibit chemotaxis of transformed cells and their invasion of a reconstituted basement membrane. Anticancer Res 1987; 7: 475-80.
27. Liotta L, Steeg P, Stetler-Stevenson W. Cancer metastasis and angiogenesis. An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
28. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983; 80: 3734-7.
29. Albini A, Soldi R, Giunciuglio D, et al. HIV-1 Tat induced angiogenesis is mediated by activation of the flk-1/KDR tyrosine kinase receptor on vascular endothelial cells. Nature Med 1996; 2: 1371-5.
30. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998; 273: 22128-35.
31. Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. Faseb J 1999; 13: 647-55.
32. Melchiori A, Allavena G, Bohm J, et al. Interferons inhibit chemotaxis of transformed cells and their invasion of a reconstituted basement membrane. Anticancer Res 1987; 7: 475-80.
33. Gohji K, Fidler IJ, Tsan R, et al. Human recombinant interferons-beta and gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 1994; 58: 380-4.
34. Hong WK, Tri LM. Retinoids in human cancer. In The retinoids: biology, chemistry and medicine, Sporn MP, Roberts AB and Goodman DS, eds. 1994; 597-630.
35. Hendrix M, Wood W, Seftor E, et al. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to ... decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 1990; 50: 4121-30.
36. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W. Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RARa mediates the antiangiogenic effect of retinoids. Cancer Lett 1995; 89: 117-24.
37. Iurlaro M, Benelli R, Masiello L, Rosso M, Albini A. Beta interferon inhibits HIV-1 Tat induced angiogenesis; synergism with 13-cis retinoic acid. Eur J Cancer 1998; 34: 570-6.